nifedipine has been researched along with Obesity in 24 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effect of trandolapril, an angiotensin converting enzyme inhibitor, on blood pressure, forearm blood flow and insulin sensitivity in comparison with nifedipine gastrointestinal therapeutic system." | 9.09 | Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). ( Capaldo, B; Carretta, R; Fabris, F; Ferrara, LA; Galletti, F; Glorioso, N; Mancini, M; Semplicini, A; Strazzullo, P, 1999) |
| " The Modern Approach to the Treatment of Hypertension (MATH) trial was conducted to determine the efficacy and safety of the new once-daily nifedipine gastrointestinal therapeutic system (GITS) formulation in a large cohort of mild-to-moderate hypertensive patients overall, and to identify specific effects of therapy in the presence of complicating factors such as diabetes and obesity." | 9.06 | Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension Study Group. ( Bravo, EL; Friedman, CP; Krakoff, LR; Tuck, ML, 1990) |
| " Nifedipine ameliorated obesity-impaired revascularization through suppressing oxidative stress and enhancing the number of EPCs." | 7.78 | Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice. ( Ishii, M; Kito, T; Kondo, M; Murohara, T; Shibata, R; Suzuki, H; Yamamoto, T, 2012) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 7.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| "Hypertension is frequently associated to abdominal obesity, and hyperinsulinism could play a role in its pathogenesis." | 5.30 | Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension. ( Avogadri, E; Camanni, F; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M; Rossetto, R, 1998) |
| "Nifedipine-treated obese males showed a mild but significant decrease in weight gain that was due to a decrease in fat deposition in both subcutaneous and abdominal depots and systolic blood pressure was significantly reduced after one month of treatment." | 5.29 | Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. ( Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993) |
| "The aim of this study was to evaluate the effect of trandolapril, an angiotensin converting enzyme inhibitor, on blood pressure, forearm blood flow and insulin sensitivity in comparison with nifedipine gastrointestinal therapeutic system." | 5.09 | Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). ( Capaldo, B; Carretta, R; Fabris, F; Ferrara, LA; Galletti, F; Glorioso, N; Mancini, M; Semplicini, A; Strazzullo, P, 1999) |
| " The Modern Approach to the Treatment of Hypertension (MATH) trial was conducted to determine the efficacy and safety of the new once-daily nifedipine gastrointestinal therapeutic system (GITS) formulation in a large cohort of mild-to-moderate hypertensive patients overall, and to identify specific effects of therapy in the presence of complicating factors such as diabetes and obesity." | 5.06 | Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension Study Group. ( Bravo, EL; Friedman, CP; Krakoff, LR; Tuck, ML, 1990) |
| " Nifedipine ameliorated obesity-impaired revascularization through suppressing oxidative stress and enhancing the number of EPCs." | 3.78 | Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice. ( Ishii, M; Kito, T; Kondo, M; Murohara, T; Shibata, R; Suzuki, H; Yamamoto, T, 2012) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 3.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| " She would like to know whether she can continue using metformin during the pregnancy and also is concerned about the effect of the gastric bypass surgery." | 3.74 | A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery. ( Coustan, DR, 2008) |
| " Accordingly, we determined the effect of Ca2+ channel blockade (nifedipine for 4 wk) on FAS and obesity in transgenic mice expressing the agouti gene in a ubiquitous manner." | 3.69 | The effects of calcium channel blockade on agouti-induced obesity. ( Kim, JH; Moore, JW; Moustaid, N; Mynatt, RL; Woychik, RP; Zemel, MB, 1996) |
| "The aim of this study was to evaluate the effects of perindopril or barnidipine alone or combined with simvastatin on metabolic parameters and hepatic steatosis degree." | 2.80 | Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015) |
| "Body weight gain was measured each week." | 1.38 | Calcium ameliorates obesity induced by high-fat diet and its potential correlation with p38 MAPK pathway. ( Liu, S; Sun, C; Wang, L; Yan, J, 2012) |
| "Hypertension is frequently associated to abdominal obesity, and hyperinsulinism could play a role in its pathogenesis." | 1.30 | Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension. ( Avogadri, E; Camanni, F; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M; Rossetto, R, 1998) |
| "Nifedipine-treated obese males showed a mild but significant decrease in weight gain that was due to a decrease in fat deposition in both subcutaneous and abdominal depots and systolic blood pressure was significantly reduced after one month of treatment." | 1.29 | Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. ( Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993) |
| " In conclusion, isolated mesenteric arteries from obese Zucker rats do not show relevant structural changes, and the pharmacodynamic behaviour of such vessels appears to be the same as that of control preparations." | 1.29 | Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats. ( Kam, KL; Pfaffendorf, M; van Zwieten, PA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, S | 1 |
| Han, D | 1 |
| Kang, HG | 1 |
| Jeong, SJ | 1 |
| Jo, JE | 1 |
| Shin, J | 1 |
| Kim, DK | 1 |
| Park, HW | 1 |
| Li, S | 1 |
| Maude-Griffin, R | 1 |
| Pullan, AJ | 1 |
| Chen, JD | 1 |
| Derosa, G | 1 |
| Mugellini, A | 1 |
| Pesce, RM | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Takahashi, F | 1 |
| Goto, M | 1 |
| Wada, Y | 1 |
| Hasebe, N | 1 |
| Yamamoto, E | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Fukuda, M | 1 |
| Nako, H | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Sun, C | 1 |
| Wang, L | 1 |
| Yan, J | 1 |
| Liu, S | 1 |
| Tian, Z | 1 |
| Miyata, K | 1 |
| Tabata, M | 1 |
| Yano, M | 1 |
| Tazume, H | 1 |
| Aoi, J | 1 |
| Takahashi, O | 1 |
| Araki, K | 1 |
| Kawasuji, M | 1 |
| Oike, Y | 1 |
| Sano, M | 1 |
| Kito, T | 1 |
| Shibata, R | 1 |
| Kondo, M | 1 |
| Yamamoto, T | 1 |
| Suzuki, H | 1 |
| Ishii, M | 1 |
| Murohara, T | 1 |
| Radin, MJ | 1 |
| Chu, YY | 1 |
| Hoepf, TM | 1 |
| McCune, SA | 1 |
| Fomin, VV | 1 |
| Safonov, VV | 1 |
| Kozlovskaia, NL | 1 |
| Moiseev, SV | 1 |
| Osipenko, VI | 1 |
| Tironishvili, OI | 1 |
| Iskenderov, BG | 1 |
| Burmistrova, LF | 1 |
| Berenshteĭn, NV | 1 |
| Lokhina, TV | 1 |
| Coustan, DR | 1 |
| Albrecht, J | 1 |
| Witt, T | 1 |
| König, G | 1 |
| Gaul, G | 1 |
| Blazek, G | 1 |
| Deutsch, E | 1 |
| Heeger, H | 1 |
| Kam, KL | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| Kim, JH | 1 |
| Mynatt, RL | 1 |
| Moore, JW | 1 |
| Woychik, RP | 1 |
| Moustaid, N | 1 |
| Zemel, MB | 1 |
| Maccario, M | 1 |
| Oleandri, SE | 1 |
| Avogadri, E | 1 |
| Rossetto, R | 1 |
| Grottoli, S | 1 |
| Procopio, M | 1 |
| Camanni, F | 1 |
| Ghigo, E | 1 |
| Galletti, F | 1 |
| Strazzullo, P | 1 |
| Capaldo, B | 1 |
| Carretta, R | 1 |
| Fabris, F | 1 |
| Ferrara, LA | 1 |
| Glorioso, N | 1 |
| Semplicini, A | 1 |
| Mancini, M | 1 |
| Valensi, P | 2 |
| Uzzan, B | 2 |
| Attali, JR | 2 |
| Perret, G | 2 |
| Andronico, G | 1 |
| Piazza, G | 1 |
| Mangano, MT | 1 |
| Mule, G | 1 |
| Carone, MB | 1 |
| Cerasola, G | 1 |
| Vassy, R | 1 |
| Tuck, ML | 1 |
| Bravo, EL | 1 |
| Krakoff, LR | 1 |
| Friedman, CP | 1 |
| Black, MA | 1 |
| Fournier, LA | 1 |
| Heick, HM | 1 |
| Bégin-Heick, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for nifedipine and Obesity
| Article | Year |
|---|---|
Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 2015 |
[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
Topics: Adult; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relation | 2007 |
Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS).
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Blood Pressure; Calcium; | 1999 |
Effects of nifedipine and nitrendipine on insulin secretion in obese patients.
Topics: Adult; Analysis of Variance; Blood Glucose; C-Peptide; Double-Blind Method; Female; Humans; Hyperten | 1991 |
Nifedipine vs. enalapril in treatment of hypertensive patients with glucose intolerance.
Topics: Blood Glucose; Cholesterol; Enalapril; Glucose; Humans; Hypertension; Insulin; Middle Aged; Nifedipi | 1991 |
Effect of nifedipine and nitrendipine on insulin release in non-diabetic obese patients: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Glucose; Humans; Insulin; Insulin Secretion; M | 1991 |
Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension Study Group.
Topics: Aged; Blood Pressure; Diabetes Complications; Electrolytes; Endocrine Glands; Female; Heart Rate; He | 1990 |
17 other studies available for nifedipine and Obesity
| Article | Year |
|---|---|
Intravenous sustained-release nifedipine ameliorates nonalcoholic fatty liver disease by restoring autophagic clearance.
Topics: Administration, Intravenous; Animals; Autophagy; Calcium Channel Blockers; Delayed-Action Preparatio | 2019 |
Gastric emptying and Ca(2+) and K(+) channels of circular smooth muscle cells in diet-induced obese prone and resistant rats.
Topics: 4-Aminopyridine; Animals; Calcium Channels; Diet; Diet, High-Fat; Gastric Emptying; Male; Myocytes, | 2013 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dia | 2010 |
Calcium ameliorates obesity induced by high-fat diet and its potential correlation with p38 MAPK pathway.
Topics: Adipogenesis; Animals; Calcium, Dietary; Cholesterol; Diet, High-Fat; Gene Expression Regulation; Im | 2012 |
Nifedipine increases energy expenditure by increasing PGC-1α expression in skeletal muscle.
Topics: Adipose Tissue; Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationshi | 2011 |
Revisiting the merits of nifedipine.
Topics: Animals; Calcium Channel Blockers; Energy Metabolism; Male; Muscle, Skeletal; Nifedipine; Obesity; P | 2011 |
Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice.
Topics: Animals; Calcium Channel Blockers; Capillaries; Dietary Carbohydrates; Dietary Fats; Endothelial Cel | 2012 |
Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Composition; Body Constitution; Body Weight; | 1993 |
[Ischemic disease of the kidneys in a patient with morbid obesity: characteristics of the course and diagnostic policy].
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Diagnosis, Differential; Health Policy; Human | 2006 |
A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery.
Topics: Adult; Antihypertensive Agents; Breast Feeding; Diabetes Mellitus, Type 2; Female; Gastric Bypass; G | 2008 |
[Diminished efficiency and narcoleptic attacks with loud snoring in severe obesity].
Topics: Diagnosis, Differential; Efficiency; Female; Humans; Middle Aged; Narcolepsy; Nifedipine; Obesity; O | 1983 |
[A case of chronic pulmonary hypertension after fenfluramine intake].
Topics: Chronic Disease; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Obe | 1982 |
Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats.
Topics: Animals; Benzopyrans; Blood Glucose; Calcium Channels; Calcium Chloride; Cromakalim; Glyburide; Hype | 1996 |
The effects of calcium channel blockade on agouti-induced obesity.
Topics: Adipose Tissue; Agouti Signaling Protein; Animals; Body Temperature; Body Weight; Calcium Channel Bl | 1996 |
Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension.
Topics: Adult; Blood Glucose; Body Constitution; Body Mass Index; Calcium Channel Blockers; Dehydroepiandros | 1998 |
Different insulin-secretory responses to calcium-channel blockers in islets of lean and obese (ob/ob) mice.
Topics: Animals; Colforsin; Dantrolene; Glucose; Insulin; Insulin Secretion; Ion Channels; Islets of Langerh | 1988 |